

PATENT ABSTRACTS OF JAPAN

(11)Publication 01-193227

n number :

(43)Date of 03.08.1989

publication of

application :

(51)Int.Cl.

A61K 37/02

(21)Applicati 63-017423
on number :

(71)Applicant RES DEV CORP OF JAPAN
GREEN CROSS CORP:THE
MORINAGA MILK IND CO LTD

(22)Date of 29.01.1988
filing :

(72)Inventor : TACHIBANA MASAOKI
TAZAKI HIROSHI

(54) ADJUVANT FOR CANCER IMMUNOTHERAPY

(57)Abstract:

PURPOSE: To obtain an adjuvant for cancer immunotherapy, containing a colony formation stimulating factor (CSF) as an active ingredient and capable of remarkably increasing antitumor effects thereof by using with an immunopotentiator in combination.

CONSTITUTION: An action enhancer for an immunopotentiator containing CSF, e.g., G-CSF, M-CSF, GM-CSF or CSF-HU, which is a proteinaceous factor capable of promoting propagation and differentiation of granulocytes or macrophages as an active ingredient. The adjuvant is capable of enhancing TNF (tumor necrosis factor) activity and sustaining the activity for a long period by using the immunopotentiator (e.g., picibanil, krestin, lenthinan or sizofilan), increasing the TNF activity through monocytes, granulocytes or lymphocytes and producing antitumor effects and CSF in combination. The CSF is dissolved in physiological saline solution for injection so as to provide 103W106 units/ml and administered by intravenous injection, drip infusion, intramuscular injection, etc. The dose thereof is within the range of 1000W150000 units/kg body weight a time.

LEGAL STATUS

[Date of request for examination]

[Date of sending the examiner's decision of rejection]

[Kind of final disposal of application other than the examiner's decision of rejection or application converted registration]

[Date of final disposal for application]

[Patent number]

[Date of registration]

[Number of appeal against examiner's decision
of rejection]

[Date of requesting appeal against examiner's
decision of rejection]

[Date of extinction of right]

Copyright (C); 1998,2000 Japan Patent Office